Glaukos GKOS SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by Glaukos in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Glaukos's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Glaukos's SG&A?
- Glaukos (GKOS) reported SG&A of $92.94M in Q1 2026.
- How has Glaukos's SG&A changed year-over-year?
- Glaukos's SG&A increased by 31.5% year-over-year, from $70.67M to $92.94M.
- What is the long-term trend for Glaukos's SG&A?
- Over 4 years (2021 to 2025), Glaukos's SG&A has grown at a 16.6% compound annual growth rate (CAGR), from $179.26M to $331.75M.
- What does SG&A mean?
- The overhead costs of running the business, including sales, marketing, and administrative support.
- How do you interpret SG&A?
- Rising SG&A relative to revenue may indicate aggressive expansion or inefficient overhead, while stable or declining ratios suggest operational leverage.
- How does SG&A compare across companies?
- Standard operating expense category; peers in growth-stage med-tech often have high SG&A due to heavy investment in sales forces.